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Endogenous opiold peptides have been implicated in the cardio-
vascular depressant actions of clonidine. The effects of clonidine
have therefore been examined in anesthetized rats after pretreat-
ment with naloxone, in morphine-dependent rats to determine if
cross-tolerance operates and in hypophysectomized rats to de-
temiine whether circulating f3-endorphin may play a role. In
normotensive and spontaneously hypertensive rats, naloxone (2
mg/kg i.v.) did not alter the blood pressure and heart rate
response curves to successive doubling doses of clonidine
(0.625-i 0 pg/kg i.v.). In normotensive and spontaneously hy-
pertensive rats made morphine-dependent (3 x 75-mg morphine
pellets s.c.), the cardiovascular responses to clonidine were not
inhibited but rather enhanced with a greater maximal response
of blood pressure and an increase in both the slope and the
maximal response ofthe dose-heart rate response curve. Plasma
clonidine levels were similar in normotensive and spontaneously
hypertensive rats and corresponding morphine-dependent rats.
In hypophysectomized rats, the effect of clonidine on blood
pressure was also enhanced with an increase in the maximal
response. The reduction in circulating norepinephnne concentra-
tions produced by clonidine was similar in all groups. These
results do not support a role for endogenous opioid peptides in
the cardiovascular actions of clonidine but do suggest that
factors in addition to a reduction in sympathetic nerve activity
may be operating.
There is considerable evidence linking the effects of the
antihypertensive drug clonidine with opioid-mediated effects.
Clonidine is a relatively selective atpha-2 adrenoceptor agonist
and produces hypotension and bradycardia by activation of
inhibitory pathways in the brain, particularly the brainstem
(Kobinger, 1978). Clonidine also produces analgesia which can
be antagonized by naloxone (Lin et at., 1980) and a withdrawal
syndrome, the cardiovascular components of which are alle-
viated by morphine (Thoolen et at., 1981). Conversely, clonidine
reverses symptoms of opioid withdrawal both in experimental
animals (Laverty and Roth, 1980; Buccafusco, 1983) and in
humans (Gold et at., 1978).
Recently, Farsang et at. (1980) reported that naloxone could
inhibit and reverse the fall in blood pressure and heart rate
produced by clonidine and a-methyldopa in conscious and
anesthetized SHR. Both clonidine and a-methylnorepineph-
rine were reported to increase the release of fl-endorphin im-
munoreactivity from brainstem slices in SHR and it was pos-
tulated that atpha adrenoceptor agonists may release f3-endor-
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phin in vivo which in turn would contribute to the fall in blood
pressure (Kunos et at., 1981). Further support for this propo-
sition was provided by the demonstration that the hypotension
after injection of a-methylnorepinephrine into the nucleus
tractus solitarius of anesthetized normotensive rats could be
antagonized by naloxone and f3-endorphin antibodies (Petty
and de Jong, 1982). Naloxone was also reported to antagonize
the hypotensive effect of clonidine in humans (Farsang et at.,
1982). On the other hand, studies have shown that naloxone
fails to alter clonidine-induced changes in blood pressure, heart
rate and sympthetic nerve firing in anesthetized cats (Shrop-
shire and Wendt, 1983) and does not change the hypotensive
effects of clonidine in normal volunteers (Watkins et at., 1980)
or hypertensive patients (Rogers and Cubeddu, 1983).
Because of these conflicting results, we proposed to re-eval-
uate the possible involvement of endogenous opioid peptides in
the cardiovascular effects of clonidine in anesthetized normo-
tensive rats and SHR. In addition to monitoring blood pressure
and heart rate responses we have measured concentrations of
circulating norepinephrine, a sensitive index of sympathetic
nerve activity. Furthermore, we have examined clonidine-in-
duced cardiovascular changes in rats made morphine-depend-
ent and in hypophysectomized rats as well as after pretreatment
with naloxone. It has been argued by Sawynock et at. (1979)
ABBREVIATION: SHA, spontaneously hypertensive rats.
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that in addition to antagonism by naloxone, cross-tolerance
with opioids such as morphine also implicates opioid peptide
mechanisms in a physiological or pharmacological response.
Also, clonidine has been shown to release immunoreactive 9-
endorphin from the anterior pituitary (Pettibone and Muellar,
1981a) and to increase plasma levels of this opioid peptide in
intact but not hypophysectomized rats (Pettibone and Muellar,
1981b). Because f-endorphin has potent hypotensive properties
after systemic administration in anesthetized rats (Lemaire et
a!., 1978), it was possible that pituitary secretion of this peptide
could contribute to the clonidine-induced hypotension.
Methods
Experimental animals. Male SITR of the Okamoto strain (300-
400 g) were obtained from St. Thomas’ Hospital (London, U.K.). Sex
and weight matched Wistar rats were obtained from Charles River
Laboratories (London, U.K.). The animals were housed at constant
temperature with a fixed light-dark schedule. Hypophysectomized and
sham-operated Wistar rats (160-200 g at the time of operation) were
obtained 1 week postoperatively from Charles River Laboratories and
used immediately. They had received food, water, rock salt and lump
sugar ad libitum. Morphine-dependence was induced by the method of
Wei et a!. (1973) and involved s.c. implantation of a pellet containing
75 mg of morphine on day 1 and two such pellets on day 2 under light
halothane anesthesia. The animals were used on day 4 or 5.
Experimental procedures. Animals were anesthetized with mac-
tin (100-110 mg/kg i.p.). A cannula was placed in the carotid artery
for recording blood pressure and for blood sampling and the exterior
jugular vein was cannulated for drug administration. The trachea also
was cannulated to facilitate respiration. Body temperature was main-
tamed with a heating blanket. Statham or Bell and Howell pressure
transducers were connected to the arterial cannulas and pulsatile blood
pressure was recorded continuously on a Grass polygraph (model 79D).
Heart rate and mean arterial pressure were determined at intervals
from the pulse pressure.
Previous experiments indicated that the maximal fall in blood pres-
sure and heart rate produced by clonidine occurred within 10 mm and
lasted for approximately 60 mm (Conway and Jarrott, 1980) and that
the maximal fall in plasma norepinephrine concentrations occurred
within 5 mm (unpublished results). This corresponds with estimates of
the elimination half-life of clonidine in rats of approximately 60 mm
after a distribution half-life of less than 5 mm (Conway and Jarrott,
1982). Under these pharmacokinetic conditions it is possible to obtain
cumulative dose-response curves and these were constructed according
to the following schedule: at 0 mm isotonic saline (1 ml/kg) or naloxone
(2 mg/kg) was administered. Doses of clonidine of 0.625, 0.625, 1.25,
2.5, 5 and 10 pg/kg were then administered successively at 10, 20, 30,
40, 50 and 60 mm, respectively. Blood samples (0.4 ml) were taken 5
mm after drug injection and mean blood pressure and heart rate were
determined 10 mm after.
Clonidine also produces an initial dose-dependent elevation in blood
pressure which is less than 4 mm in duration (Conway and Jarrott,
1980) and corresponds to the rapid distribution phase of the drug. This
pressor response does not influence the prolonged fall in blood pressure
after clonidine administration and has not been analyzed further.
The dose of naloxone selected (2 mg/kg) is identical to that used by
Farsang et at. (1980) to antagonize the responses of clonidine in SHR
and twice that used by Petty and de Jong (1982) to inhibit the
cardiovascular effects of centrally administered a-methylnorepineph-
rifle. The half-life of naloxone in rats is similar to that of clonidine
(Misra et al., 1976; Tepperman et al., 1983) and in a previous study in
the same rat strain naloxone (0.8 mg/kg i.a.) was effective in blocking
the actions of exogenously applied opioids for over 60 mm (Conway et
al., 1983).
Blood was not sampled after injections of 5 and 10 ag/kg of clonidine
as preliminary studies had shown that no further fall in plasma nor-
epinephrine occurred. Total blood volume sampled was 2 ml, approxi-
mately 15% of the circulating volume, but this was replaced with the
drug injection volume (1 mI/kg) plus additional isotonic saline. In a
series of control experiments in Wistar rats, successive doses of isotonic
saline were administered on the same schedule. Plasma was separated
from blood samples and stored at -80’C until measurement of plasma
norepinephrine levels as described by Brown and Jenner (1981).
Differences were found in the cardiovascular responses to clonidine
in SHR and in morphine-dependent rats. Because these could result
from altered pharmacodynamic handling of the drug, plasma clonidine
levels were determined in rats anesthetized and cannulated according
to the above procedures. A dose of 20 ag/kg of clonidine was injected
and blood was sampled at 1, 5, 15 and 30 mm. Plasma was stored at
-20’C until assay for clonidine by radioimmunoassay (Conway and
Jarrott, 1980).
Drugs used were clonidine hydrochloride (Boehringer Ingelheim,
Germany), naloxone hydrochloride (Du Pont, Wilmington, DE) and
mactin [5-ethyl-5(1-methyl-propyl)-2-thiobarbitone sodium] kindly
donated by Dr. Pittman (Byk Gulden, Konstanz, Germany). Morphine
tablets were supplied by Dr. S. Hart (Chelsea College, London) and
clonidine antibodies by Dr. B. Jarrott (University of Melbourne, Mel-
bourne, Australia).
Statistical procedures. All data are expressed as means ± S.E.M.
Mean blood pressure and heart rate measurements for the dose-re-
sponse curves have been represented as percentage of decreases com-
pared to time zero.
The statistical procedure used to analyze the dose-response curves
has been described by Wallenstein et at. (1980). In essence, the dose-
response data obtained from each animal are summarized by one or
more parameters. These parameters are subsequently grouped and
comparisons made between the groups. The parameters that were
calculated from the data obtained in each rat were: 1) the slope of the
dose-response curve. This was determined by least-squares linear
regression analysis of the first 4 points on the curve as these points
best described the linear portion of the curve. Comparisons of the
slopes between groups is informative of differences in trends (Wallen-
stein et at., 1980) and in the present study indicate differences in the
decrease in blood pressure per unit dose. In two cases heart rat data
could not be described by a straight line so this data was omitted from
the comparisons between groups. 2) The mean of the responses repre-
sented as  response/n ; a = the number of responses. However, to be
consistent with the slope calculations only the first 4 points were used.
In the present study this parameter provides an index ofthe magnitude
of the decrease in blood pressure, heart rate or plasma norepinephrine
produced by clonidine over a set range of doses.
For the decrease in plasma norepinephrine levels only the mean
response  response/n) was calculated.
Comparisons of these parameters between groups were made either
by unpaired t test or two-way analysis of variance. In the experiments
in which plasma concentrations of clonidine were determined, the area
under the plasma concentration vs. time curve was calculated and
compared between groups by two-way analysis of variance.
Results
Effect of naloxone on clonidine responses in normo
tensive rats and SHR. Mean arterial blood pressure in the
SHR was 190 ± 4.5 mm Hg (n = 15) compared to 116 ± 3.7
mm Hg (n = 15). in normotensive rats and heart rates were 357
± 9.5 bpm (n = 15) and 360 ± 5.8 bpm (n = 15), respectively.
Clonidine produced a dose-dependent fall in blood pressure and
heart rate in both groups of rats and these responses were
virtually unchanged after administration of naloxone (2 mgI
kg) (fig. 1). Analysis of the dose-response curves indicated that
naloxone had no significant effect on either the slopes or
responses/n (tables 1 and 2). However, there was a highly
significant increase in both slope and  response/n ofthe blood






rats. This is illustrated by the steeper dose-response curve and
the higher plateau observed in SHR (fig. 1). Heart rate re-
sponses were not different in the two groups (table 2).
Clonidine also produced a dose-dependent fall in plasma
norepinephrine concentrations. This effect was variable at the
lower doses of clonidine and  response/n varied quite mark-
F I I I 1 edly within rat groups as indicated by the large S.E.M. (table
3). Hence, although naloxone reduced  response/n in normo-
tensive animals, this effect was not significant. Control plasma
norepinephrine concentrations were significantly elevated in
SHR compared to normotensive rats; however, the percentage
of reduction in these levels produced by clonidine ( response!
n) was identical in the two groups (table 3).
In normotensive rats successive injections of isotonic saline
produced no significant effects on plasma norepinephrine con-
centrations (table 3). Blood pressure was reduced slightly by a
maximum of 9.1% and heart rate decreased by 3.1% which was
not significant (data not shown).
Effects of clonidine in normotensive rats and SHR
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made morphine-dependent. In figure 2 the blood pressure
and heart rate responses to successive doses of clonidine are
shown in morphine-dependent normotensive rats and SHR and
their corresponding untreated controls. Preinjection levels of
blood pressure and heart rate were unchanged in the normoten-
sive rats made morphine-dependent [116 ± 3.7 mm Hg (n =
15) cf., 110 ± 4.8 mm Hg (n = 8) and 357 ± 10 bpm of 351 ±
10 bpmj. In SHR, blood pressure was not significantly different
in the group made morphine-dependent [168 ± 11 mm Hg, ci.
(n = 7), 190 ± 5 mm Hg (n = 15)]; however, heart rate was
slightly reduced (319 ± 13.6 bpm, cf., 360 ± 5.8 bpm, P < .05).
Morphine dependence produced an upward shift in the blood
pressure response curves illustrated by no change of slopes but
a highly significant increase in the  response/n parameter of
the curves (table 1). Thus, in morphine-dependent rats of both
TABLE 3
Effect of clonidine administration on plasma norepinephrine levels



















































































a NT, normotensive; NAL naloxone(2 mg/kg); MPD, morphine-dependent; HYP,
hypophysectomized.
a Control norepinephrine concentrations: two-way analysis of vanance between
NT and SHR indicated a significant difference between NT and SHR (F ratio =
3.60, F probability = .041)but not between treatments (F ratio = 0.64, F probability
=53).
C : response/n: two-way analysis of variance indicated no significant effect of
either strain (F ratio = 1 .51 . F probability = .24) or pretreatment (F ratio = 0.67, F
probability = .52).
d NT-placebo, successive administration of isotonic saline instead of clonidine.
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Fig. 1. Effects of clonidine on mean arterial blood pressure and heart
rate after pretreament with isotonic saline (-) or naloxone (2 mg/kg
i.v.)(- - -) in anesthetized normotensive rats(NT) or SHR. Blood pressure
and heart rate changes were determined 10 mm after increasing doses
of clonidine i.v.
TABLE 1
Summary of blood pressure dose-response curves to clonidine in
anesthetized rats
Slope response/n n
NT 23.6 ± 2.62 19.0 ± 2.62 8
NT + NAL 25.7 ± 4.02 14.8 ± 2.23 7
SHR 40.4 ± 4.58b 36.0 ± 3.58b 8
SHR + NAL 47.2 ± 6.61 32.5 ± 4.38 7
NT-MPD 30.8 ± 5.06c 35.3 ± 3.20c 8
SHR-MPD 42.2 ± 4.70 44.4 ± 1 .78 7
. NT, normotensive; NAL, naloxone (2 mg/kg); MPD, morphine-dependent.
a Two-way analysis of variance of rat strains and pretreatment with naloxone
indicated no effect of naloxone on either slope (F ratio = 0.96, F probability = .34)
or  response/n (F ratio = 1.37, F probability = .25), but a highly significant
difference in both slope (F ratio = 17.34, F probability = .0003) and  response/n
(F ratio = 27.65, F probability = .00002) between SHR and normotensive rats.
C Two-way analysis of variance of rat strains and presence or absence of
morphine dependence again indicated a similar separation on strain (Statistics not
shown). In morphine-dependent rats the slopes were not different (F ratio = 1.17,
F probability = .29) but there was a significant separation in the  response/n (F
ratio = 17.92, F probability = .00024).
TABLE 2
Summary of heart rate dose-response curves to clonidine in
anesthetized rats
Slope >.:Response/n n
NT 13.3 ± 2.1 1 1 1 .4 ± 2.95 8
NT+NAL 16.3±2.25 9.5±2.15 7
SHR 14.8 ± 2.26b 10.0 ± 1.9gb 8
SHR-NAL 12.7 ± 2.97 6.5 ± 2.50 6
NT-MPD 22.8 ± 4.40c 20.7 ± 2.27c 7
SHR-MPD 27.2 ± 2.99 18.3 ± 2.74 7
a NT, normotensive; NAL. naloxone (2 mg/kg); MPD, morpine-dependent.
b Two-way analysis of variance of rat strains and pretreatment with naloxone
indicated no effect of naloxone on either slope (F ratio = 0.05, F probability = .83)
orresponse/n(Fratio= 1.13,Fprobability= .30)andalsonodifferencein slope
(Fratio= 0.09,Fprobability= .77)or  response/n(Fratio = 0.71,Fprobability
= .41) between SHR and normotensive rats.
C Two-way analysis of variance of rat strains and presence or absence of
morphine-dependence again indicated no separation on strain (Statistics not
shown). However, in rats made morphine-dependent there was a highly significant
separationonbothslope(Fratio= 13.57,Fprobability= .0011)and response/
n(Fratio=12.19,Fprobabihty=.0017).
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Fig. 2. Effects of clonidine on mean arterial blood pressure and heart
rate in untreated (-) and morphine-dependent (- - -) normotensive
rats (NT) and SHR. BlOOd pressure and heart rate changes were deter-
mined 1 0 mm after increasing doses of clonidine iv.
50 slope : responselN
 hyp 23.9±1.2 (10) 37.2±4.3*
  sham 20. 9±2. 3 (5) 17. 65. 0

0 _________________________________
20 hyp 6.8+1.1 (10) 8.6+2.3
   sham 7.5±2.0 (5) 6.4±1.9
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Fig. 3. Effects of clonidine on mean arterial blood pressure and heart
rate in sham-operated (-) and hypophysectomized (- - -) anesthe-
tized normotensive rats. Blood pressure and heart rate changes were
determined 10 mm after increasing doses of clonidine iv. Slope and
response/n of the dose-response curves were calculated as described
under Methods” and compared by unpaired t test.   < .05.
01 5 15 30
Time mm
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Discussion
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strains there is a significant enhancement of the blood pressure
response. There was also a significant enhancement of the
heart rate response to clonidine produced by morphine depen-
dence. This included not only an increase in  response/n but
also a significantly steeper slope (table 2).
The effect of clonidine on plasma norepinephrine concentra-
tions was similar in each group of rats (table 3).
Effects of clonidine in hypophysectomized rats. Prein-
jection blood pressure in hypophysectomized rats was not sig-
nificantly different from that in sham-operated controls [92 ±
5 mm Hg (n = 10), cf., 101± 8 mm Hg (n = 5)]; however, heart
rate levels were approximately 30% lower (279 ± 12 bpm, ci.,
384 ± 17 bpm, P < .0001). Heart rate responses to successive
increasing doses of clonidine were virtually identical in the two







Fig. 4. Plasma clonidine levels after clonidine (20 pg/kg iv.) in anesthe-
tized rats. NT, normotensive rats; MPD, morphine-dependent rats. Two-
way analysis of variance of areas under curve (AUC) indicated no
significant differences in rat strains (F ratio = 0.08, F probability = .75)
or in pretreatment (F ratio = 0.49, F probability = .50).
response curves were similar, there was a greater maximal
response to clonidine in the hypophysectomized rats reflected
in the significant increase in  response/n of this group corn-
pared to sham-operated rats (fig. 3).
Plasma norepinephrine concentrations were not determined
in sham-operated rats; however, the effect of clonidine on
plasma norepinephrine concentrations in hypophysectomized
rats compared to normotensive rats was not significantly dif-
ferent (table 3).
Plasma clonidine levels in normotensive rats, SHR and
corresponding morphine-dependent groups. The disap-
pearance of clonidine in all four groups of rats showed approx-
imately the same time-course (fig. 4). The area under the
plasma concentration curves was compared using two-way anal-
ysis of variance and there was no significant difference between
either normotensive rats and SHR or between nontreated- and
morphine-dependent rats (fig. 4).
In the studies presented here naloxone at an effective dose
(see “Methods”) did not modify the clonidine-induced decreases
in blood pressure, heart rate and plasma norepinephrine con-
centrations in anesthetized normotensive rats and SHR. Fur-
thermore, rather than there being any inhibition of these re-
sponses in the corresponding morphine-dependent rat groups
or in hypophysectomized animals (see introductory section),
there was an enhancement of the hypotensive and bradycardic
effects even though clonidine levels were similar. These results
argue against there being any role of endogenous opioid pep-
tides in mediating the cardiovascular responses to clonidine
and support previous findings in anesthetized rats (Gomes et
at., 1976), cats (Shropshire and Wendt, 1983) and in humans
(Watkins et at., 1980; Rogers and Cubeddu, 1983). In additional
studies in anesthetized cats there was no evidence that nalox-
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one administered either into a lateral cerebral ventricle, the
cisterna magna or the peripheral circulation antagonized the
hypotension produced by clonidine (W. Feldberg and E. L.
Conway, unpublished observations).
Farsang et at. (1980) have reported that naloxone does inhibit
the clonidine-induced hypotension and bradycardia in con-
scious and anesthetized SHR but not in normotensive rats.
The latter finding is in agreement with the present results but
those in SHR are different. In their studies in conscious rats
the indirect tail-cuff procedure was used to determine blood
pressure and heart rate. This method has been shown to pro-
duce a greater elevation in blood pressure and circulating
cateeholamines in SHR than in normotensive rats when corn-
pared to direct recordings in resting animals (Chiueh and
Kopin, 1978). This hyper-responsiveness to stress may explain
the discrepancy in results. Stress-induced analgesia is a well
documented phenomenon (Madden et at., 1977; Amir et at.,
1980; Grau et at., 1981) and has been associated with release of
opioid peptides from the pituitary (Lim and Funder, 1983) and
the adrenal medulla (Lewis et at., 1982). If these circulating
opioid peptides have cardiovascular depressant effects as has
been demonstrated in pharmacological studies (Lemaire et at.,
1978; Moore and Dowling, 1980; Sitsen et at., 1982), then effects
of naloxone on clonidine responses observed by Farsang et at.
(1980) may represent a more complex interaction than has been
supposed. Also, reversal of any stress-induced analgesia might
complicate the cardiovascular responses to clonidine in con-
scious animals.
The different results in anesthetized animals are difficult to
explain. Farsang et at. (1980) used rats lightly anesthetized with
pentobarbital. In the present study mactin was used which,
although also a barbiturate, produces less reduction in blood
pressure and a more stable anesthesia for cardiovascular studies
than does pentobarbital (unpublished observations). Anesthetic
interactions may therefore explain the different results.
Enhanced cardiovascular responses to clonidine in SHR com-
pared to other strains of rats have been documented previously
(Dadkar et at., 1979; Farsang et at., 1980); however, the effect
of morphine dependence in enhancing responses in both groups
of rats was surprising. Chronic morphine administration in rats
decreases sensitivity to the inhibitory effect of morphine on
stimulation-induced contractions in isolated vasa deferentia,
whereas there is concomitant development of supersensitivity
to norepinephrine (Rae and de Moraes, 1983). Moreover,
chronic morphine treatment increases the number of alpha-2
adrenoceptor binding sites in rat brain (Hamburg and Tailman,
1981). Because clonidine acts via atpha-2 adrenoceptors to
produce a fall in blood pressure (see introductory section), the
present findings lend support to this observation and suggest
that there may also be an increase in the number of functional
alpha-2 adrenoceptors in the brain. Opioid substances decrease
catecholamine release in vitro (Gaddis and Dixon, 1982; Jones
and Marchbanks, 1982; Saiani and Guidotti, 1982) and can also
reduce norepinephrine turnover in brain (Gomes et at., 1976;
Fuxe et at., 1979) and decrease firing rates in the locus ceruleus
(Aghajanian, 1978). Thus, a prolonged suppression of norad-
renergic activity may explain the increase in alpha-2 adreno-
ceptors.
Although previous studies had implicated central opioid pep-
tides as potential contributors to the hypotensive action of
clonidine (Kunos et at., 1981), it was possible that pituitary
release of fl-endorphin might also play a role (see introductory
section). We found no evidence ofthis but rather an unexpected
increase in responsiveness of blood pressure in hypophysecto-
mixed compared to sham-operated rats. Enhanced hypotensive
effects of clonidine have been reported in sodium-depleted rats
(Pals, 1975); however, this is unlikely to explain the present
results as rats were maintained on salt before the experiments.
Further study will be required to determine which pituitary
factors influence the altered response to clonidine.
Until recently the centrally mediated fall in blood pressure
produced by clonidine has been attributed to a decrease in
sympathetic nerve activity (Klupp et at., 1970; Loew and Waite,
1974; Tangri et at., 1977). However, there are discrepancies
between the time course of clonidine-induced hypotension and
reduced sympathetic nerve activity (Schmitt, 1975; Laubie et
at., 1976) and between the hypotension and the reduction in
circulating norepinephrine concentrations (Louis et at., 1983).
In the present studies, despite significant differences in the
cardiovascular responses to clonidine, the dose-dependent re-
duction in plasma norepinephrine concentrations was not sig-
nificantly different in any of the groups. These results support
the possibility that a factor in addition to a reduction in
sympathetic nerve activity may be operating in clonidine-in-
duced hypotension. However, they do not implicate endogenous
opioid peptides as this factor.
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